



ABBOTT

Garyleda Ferrari-Dileo, Ph.D
Legal Division
Patents & Trademarks

Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064-6008

Telephone: (847) 935-1729
FAX: (847) 938-2623

FACSIMILE COVER SHEET

DATE: November 10, 2004

TO: Francine P. Mercer
Group Art Unit 1623

FROM: Gabryleda Ferrari-Dileo, Ph.D.
Patents and Trademarks
D-0377, AP6A-1
Telephone: (847) 935-4314

PHONE NUMBER OF TELECOPY MACHINE: 571-273-0541

TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 12

MESSAGE:

RE: Serial No.: 10/634,678
Filed: August 5, 2003

For: FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR
SUBTYPE 1 (VR1) RECEPTOR

Transmitting:

Transmittal Letter – 1 pg. (in duplicate)
Response to Notice of Non-Compliant Amendment – 9 pgs.

THIS TRANSMISSION IS INTENDED ONLY FOR THE INDIVIDUAL(S) TO WHOM IT IS ADDRESSED.

It may contain confidential information, attorney work product, or other privileged material. If you are not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this transmission is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone at (847) 935-7562 and return the transmission to us at the address listed above.

©Abbott Laboratories, 1991. All rights reserved. IF YOU DO NOT RECEIVE ALL PAGES AS INDICATED, PLEASE CALL (847) 935-7562

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chih-Hung Lee, et al.

Serial No.: 10/634,678

Filed: August 5, 2003

For: FUSED AZABICYCLIC COMPOUNDS
THAT INHIBIT VANILLOID RECEPTOR
SUBTYPE 1 (VR1) RECEPTOR

Examiner: Lawrence E. Crane

Group Art Unit: 1623

Attorney Docket No.: 6888.US.P1

Date: November 10, 2004

**Certificate of Facsimile Transmission under 37
CFR §1.8(a):**

I hereby certify that this paper (along with any
paper referred to as being attached or enclosed) is
being transmitted via facsimile, said transmission
to be completed before midnight Eastern time on
the date shown below, addressed to the following
recipient:

Commissioner for Patents
Attn: Examiner Francine P. Mercer
Group Art Unit 1623
Alexandria, VA 22313-1450

Recipient Telefax Number: 571-273-0541

Wanda E. Smith 11/10/04
Wanda E. Smith Date

TRANSMITTAL LETTERCommissioner for Patents
Attn: Francine P. Mercer
Group Art Unit 1623
Alexandria, VA 22313-1450


Dear Sir/Madame:

Enclosed herewith for the patent application identified above, entitled FUSED AZABICYCLIC
COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
are the following:

1. Response to Notice of Non-Compliant Amendment (9 Pages)

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37
CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated
with this communication for which full payment had not been tendered, to Deposit Account No.
01-0025. A duplicate copy of this sheet is enclosed.

23492Respectfully submitted,
Chih-Hung Lee, et al.ABBOTT LABORATORIES
Telephone: (847) 935-4314
Facsimile: (847) 938-2623



Gabryleda Ferrari-Dileo
Registration No. 55,174
Attorney for Applicants

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chih-Hung Lee, et al.

Serial No.: 10/634,678

Filed: August 5, 2003

For: FUSED AZABICYCLIC COMPOUNDS
THAT INHIBIT VANILLOID RECEPTOR
SUBTYPE 1 (VR1) RECEPTOR

Examiner: Lawrence E. Crane

Group Art Unit: 1623

Attorney Docket No.: 6888.US.P1

Date: November 10, 2004

Certificate of Facsimile Transmission under 37
CFR §1.8(a):I hereby certify that this paper (along with any
paper referred to as being attached or enclosed) is
being transmitted via facsimile, said transmission
to be completed before midnight Eastern time on
the date shown below, addressed to the following
recipient:Commissioner for Patents
Attn: Examiner Francine P. Mercer
Group Art Unit 1623
Alexandria, VA 22313-1450

Recipient Telefax Number: 571-273-0541

Wanda C. Smith 11/10/04
Wanda E. Smith DateTRANSMITTAL LETTERCommissioner for Patents
Attn: Francine P. Mercer
Group Art Unit 1623
Alexandria, VA 22313-1450


Dear Sir/Madame:

Enclosed herewith for the patent application identified above, entitled FUSED AZABICYCLIC
COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
are the following:

I. Response to Notice of Non-Compliant Amendment (9 Pages)

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37
CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated
with this communication for which full payment had not been tendered, to Deposit Account No.
01-0025. A duplicate copy of this sheet is enclosed.

23492

Respectfully submitted,
Chih-Hung Lee, et al.ABBOTT LABORATORIES
Telephone: (847) 935-4314
Facsimile: (847) 938-2623

Gabriylda Ferrari-Dileo
Registration No. 55,174
Attorney for Applicants

**PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Chih-Hung Lee, et al.

Serial No.: 10/634,678

Filed: August 5, 2003

For: FUSED AZABICYCLIC COMPOUNDS
THAT INHIBIT VANILLOID RECEPTOR
SUBTYPE 1 (VR1) RECEPTOR

Examiner: Lawrence E. Crane

Group Art Unit: 1623

Attorney Docket No.: 6888.US.P1

Date: November 10, 2004

**Certificate of Facsimile Transmission under 37
CFR §1.8(a):**

I hereby certify that this paper (along with any
paper referred to as being attached or enclosed) is
being transmitted via facsimile, said transmission
to be completed before midnight Eastern time on
the date shown below, addressed to the following
recipient:

Commissioner for Patents
Attn: Examiner Francine P. Mercer
Group Art Unit 1623
Alexandria, VA 22313-1450

Recipient Telefax Number: 571-273-0541

Wanda C. Smith 11/10/04
Wanda E. Smith Date

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT (37 CFR 1.121)Commissioner for Patents
Attn: Francine P. Mercer
Group Art Unit 1623
Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice of Non-Compliant Amendment, dated October 26, 2004, in the
patent application identified above, please find the corrected section of the non-compliant
amendment as follows:

Corrected Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 2 of this paper.